Lu-PSMA I&T
Phase 2Small molecule
Lu-PSMA I&T is one of 69 small molecule programs targeting Oligometastatic. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
Xaluritamig
AmgenPhase 3
Radium-223
BayerPhase 3
Perflutren Lipid Microspheres
SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3
AAA817
NovartisPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Lu-PSMA I&T
MMedical University of Vienna
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic1 trial
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:
Active, not recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT05867615·83 enrolled
Prostate Cancer1 trial
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT05893381·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu-PSMA I&T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMedical University of Vienna